Additive manufacturing and medical software and 3D printing services company Materialise NV (MTLS:NASDAQ) today reported financial results for the fourth quarter and full year of 2020 ended December 31, 2020.
Materialise stated that in Q4/20 total revenue decreased by 10.7% to 45.301 million euros, compared to 50.712 million euros in Q4/19. The firm noted, however, that total revenues in Q4/20 increased by 11.1% compared to Q3/20.
During the same corresponding period the firm advised that adjusted EBITDA decreased to 7.370 million euros compared to 7.749 million euros in the previous year's quarter, although the adjusted EBITDA margin improved to 16.3% in Q4/20 versus 15.3% in Q4/19.
The firm reported that for Q4/20 it posted a net loss of 2.118 million euros, or 0.04 euros per diluted share, compared to a net profit of 1.246 million euros, or 0.03 euros per diluted share in Q4/19.
For FY/20, the company reported total revenue decreased by 13.3% to 170.449 million euros, compared to 196.679 million euro on FY/19 and adjusted EBITDA of 20.378 million euros, versus 26.656 million euros in the same period.
The firm stated for FY/20 it posted a Net loss in the amount of 7.272 million euros, 0.13 euros per diluted share, compared to a Net profit of 1.644 million euros, 0.03 euros per diluted share in FY/19.
Materialise NV's Executive Chairman Peter Leys remarked "The COVID-19 pandemic made 2020 an incredibly challenging year for economies worldwide, our customers, our business and our employees. For the first time in Materialise's 30-year history, revenues decreased year over year. While uncertainty remains, we are encouraged by the fact that our Q4/20 revenues grew double digits sequentially and that, over the same period, our deferred revenues from software license and maintenance fees grew by 3.4 million euros...In spite of the pandemic headwinds, we believe our continued R&D efforts and strategic investments position us well to expand our existing business and capture new growth opportunities as our company enters its fourth decade and the additive manufacturing market continues to develop."
The company indicated that on November 9, 2020, it acquired the remaining 50% of shares that it did not own already in RS Print, which owns the Phits personalized insole product line and essentially 100% of the assets of RS Scan. The firm commented that RS Scan "is a market leader in the development and supply of intelligent foot measurement technology and systems."
The company provided some forward guidance and stated that for Q1/21 it expects that both the Software and Medical segments will continue to rebound steadily and may reach the same levels recorded in Q1/20 pre-pandemic. The firm advised that at present it does not anticipate that its Manufacturing segment will recover quite as quickly. Materialise stated that based upon those projections it expects that Q1/21 consolidated revenues will be 5-10% lower than Q1/20 revenues. The firm added that the outlook for the rest of FY/21 looks brighter after the COVID-19 crisis subsides when it expects that the entire group including its Manufacturing segment will perform strongly and grow sequentially.
Materialise NV is headquartered in Leuven, Belgium, and is a provider of additive manufacturing software and three dimensional (3D) printing services that together form a backbone for the 3D printing industry. The firm utilizes its 30 years of 3D printing experience to offer open and flexible solutions which allows companies in many different industries including aerospace, automotive, art and design, consumer goods and healthcare to create and build innovative 3D printing applications. The firm provides the tools to help customers transition toward a digital manufacturing process and speed innovation.
The company operates in Belgium and numerous other countries worldwide including Australia, Austria, Brazil, China, Colombia, France, Germany, Japan, Malaysia and Poland.
Materialise began the day with a market capitalization of around $1.6 billion with approximately 53.17 million shares outstanding and a short interest of about 1.0%. MTLS ADR shares opened 9% higher today at $33.00 (+$2.7, +9.09%) over yesterday's $30.25 closing price. The stock has traded today between $32.50 and $38.97 per share and is closed for trading at $38.38 (+$8.13, +26.88%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
